In Brief: ArthroCare/Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Enter agreement under which Boston Scientific acquires exclusive licensing rights to develop and market ArthroCare's Coblation technology for use in myocardial revascularization. Boston Scientific will pay licensing fees to Sunnyvale, California-based ArthroCare upon achievement of designated clinical and regulatory milestones, and royalties on sales of resulting products. Specific terms of the agreement were not disclosed. ArthroCare began marketing the technology in December 1995 for use in arthroscopic surgery following FDA clearance ("The Gray Sheet" Jan. 26, 1996, p. 22)...
You may also be interested in...
Stryker Licenses ArthroCare Coblation Technology Following Serfas Launch
Stryker Corp. agreed to license ArthroCare's Coblation radiofrequency arthroscopy technology just days after its mid-June launch of the competing Serfas arthroscopy product in order to head-off a patent infringement suit, ArthroCare says.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.